查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1608967

吸收不良症候群市場：按治療方法、疾病類型和最終用戶分類 - 全球預測 2025-2030

Malabsorption Syndrome Market by Treatment (Anti-Inflammatory Drugs, Antibiotics, Antidiarrheal Agents), Disease Type (Cystic Fibrosis, Lactose Intolerance, Sprue), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

吸收不良症候群市場價值 2023 年為 23.4 億美元，預計到 2024 年將達到 24.9 億美元，複合年成長率為 5.66%，到 ​​2030 年將達到 34.5 億美元。

吸收不良症候群包括多種以腸道無法充分吸收食物中的營養素、維生素和礦物質為特徵的疾病。強調解決這種綜合症的必要性，因為它可能導致嚴重的營養缺乏，從而導致對診斷和治療方案的需求增加。其應用涵蓋醫療保健領域，特別是胃腸保健產品、營養食品和醫療診斷。主要最終使用者包括診斷、治療和管理吸收不良相關病症的醫院、診所和專科醫療中心。吸收不良症候群管理市場主要是由胃腸道疾病盛行率上升、人口老化容易營養不良以及消化健康意識不斷增強所推動。診斷工具和治療方案的技術進步為市場成長提供了有利可圖的機會。例如，開發先進的診斷影像技術和非侵入性檢測方法以進行早期診斷非常重要。對旨在解決特定缺陷的營養食品的需求激增也支持了成長。然而，市場開拓面臨治療成本上升、新興國家意識缺乏、醫療基礎建設落後等重大挑戰。此外，準確診斷這種症候群的複雜性阻礙了及時治療，從而阻礙了市場動力。這個市場充滿了創新和研究的機會，特別是在開發整合飲食管理和藥物治療的綜合治療方法方面。公司還可以從投資更容易獲得和更具成本效益的診斷解決方案中受益。隨著市場的發展，包括尖端研究、產品開發和患者教育舉措在內的多學科方法將被證明是非常有利的。建議加強與醫療保健提供者的合作，以提高診斷和治療的可近性，作為開拓潛在細分市場和推動成長的策略舉措。

主要市場統計
基準年[2023] 23.4億美元
預計年份 [2024] 24.9億美元
預測年份 [2030] 34.5億美元
複合年成長率（%） 5.66%

市場動態：快速發展的吸收不良症候群市場的關鍵市場洞察

吸收不良症候群市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 乳糖不耐症消費者增加
    • 積極的政府措施和針對吸收不良症候群的宣傳活動
    • 消化器官系統疾病（例如乳糜瀉）增加
  • 市場限制因素
    • 缺乏足夠的醫療基礎設施
  • 市場機會
    • 增加治療吸收不良症候群的監管核准和臨床試驗
    • 新藥投資及開發
  • 市場挑戰
    • 嚴格的安全法規和產品召回

波特的五力：駕馭吸收不良症候群市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解吸收不良症候群市場的外部影響

外部宏觀環境因素在塑造吸收不良症候群市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解吸收不良症候群市場的競爭狀況

對吸收不良綜合症市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣吸收不良症候群市場供應商的績效評估

FPNV 定位矩陣是評估吸收不良症候群市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃吸收不良症候群市場的成功之路

吸收不良症候群市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 乳糖不耐症消費者增加
      • 針對吸收不良症候群的有利政府措施和宣傳宣傳活動
      • 乳糜瀉和其他消化系統疾病等致病疾病的發生率增加
    • 抑制因素
      • 缺乏足夠的醫療基礎設施
    • 機會
      • 吸收不良症候群治療的監管核准和臨床試驗增加
      • 新藥投資及開發
    • 任務
      • 嚴格的安全法規和產品召回
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章吸收不良症候群市場的治療

  • 發炎藥
  • 抗生素
  • 止瀉藥
  • 無麩質飲食
  • 食品補充品
  • 蛋白酶和脂肪酶補充品

第7章吸收不良症候群市場：依疾病類型

  • 囊腫纖維化
  • 乳糖不耐症
  • 澆口

第 8 章吸收不良症候群市場：依最終用戶

  • 學術研究所
  • 醫院
  • 營養診所
  • 製藥公司

第9章美洲吸收不良症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區吸收不良症候群市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲/中東/非洲吸收不良症候群市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbvie Inc.
  • Ache Laboratorios Farmaceuticos SA
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Koninklijke Philips NV
  • Merck & Co., Inc.
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Sanofi SA
  • Tillotts Pharma AG
Product Code: MRR-4659C8711BBE

The Malabsorption Syndrome Market was valued at USD 2.34 billion in 2023, expected to reach USD 2.49 billion in 2024, and is projected to grow at a CAGR of 5.66%, to USD 3.45 billion by 2030.

Malabsorption Syndrome encompasses a range of disorders characterized by the intestine's inability to adequately absorb nutrients, vitamins, and minerals from food. The necessity of addressing this syndrome is underscored by its potential to cause severe nutritional deficiencies, leading to an increased demand for diagnostics and treatment options. Its applications span the healthcare sector, particularly focusing on gastrointestinal health products, dietary supplements, and medical diagnostics. Key end-users include hospitals, clinics, and specialized medical centers that diagnose, treat, and manage malabsorption-related conditions. The market for Malabsorption Syndrome management is primarily driven by the rising prevalence of gastrointestinal disorders, aging populations more prone to nutrient deficiencies, and increasing awareness regarding digestive health. Technological advancements in diagnostic tools and treatment options present lucrative opportunities for market growth. For instance, the development of advanced imaging techniques and non-invasive testing methods for early diagnosis is critical. Growth is also supported by a surge in demand for nutritional supplements designed to counter specific deficiencies. However, market expansion faces significant challenges, such as high treatment costs, lack of awareness in developing regions, and inadequate healthcare infrastructure. Furthermore, the complexity of accurately diagnosing the syndrome can impede timely treatment, hindering market momentum. Innovation and research opportunities abound within this market, especially in formulating comprehensive treatment regimens that integrate dietary management with pharmacotherapy. Companies can also benefit from investing in more accessible and cost-effective diagnostic solutions. With the market's evolving nature, a multidisciplinary approach encompassing cutting-edge research, product development, and patient education initiatives could prove highly advantageous. Strengthening collaborations with healthcare providers to enhance diagnosis and treatment accessibility is recommended as a strategic move to tap into potential market segments and foster growth.

KEY MARKET STATISTICS
Base Year [2023] USD 2.34 billion
Estimated Year [2024] USD 2.49 billion
Forecast Year [2030] USD 3.45 billion
CAGR (%) 5.66%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Malabsorption Syndrome Market

The Malabsorption Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of lactose intolerance consumers
    • Favorable government initiatives and awareness campaigns for malabsorption syndrome
    • Growing incidences of cause disorders such as celiac disease and other digestive diseases
  • Market Restraints
    • Lack of proper healthcare infrastructure
  • Market Opportunities
    • Increasing regulatory approvals and clinical trials of treating malabsorption syndrome
    • Investments and development of novel medicines
  • Market Challenges
    • Stringent safety rules and product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Malabsorption Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Malabsorption Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Malabsorption Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Malabsorption Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Malabsorption Syndrome Market

A detailed market share analysis in the Malabsorption Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Malabsorption Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Malabsorption Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Malabsorption Syndrome Market

A strategic analysis of the Malabsorption Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Malabsorption Syndrome Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Ache Laboratorios Farmaceuticos S.A., AstraZeneca PLC, Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Koninklijke Philips N.V., Merck & Co., Inc., Novartis AG, Perrigo Company PLC, Pfizer Inc., Sanofi S.A., and Tillotts Pharma AG.

Market Segmentation & Coverage

This research report categorizes the Malabsorption Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Anti-Inflammatory Drugs, Antibiotics, Antidiarrheal Agents, Gluten-Free Diet, Nutritional Supplements, and Protease & Lipase Supplements.
  • Based on Disease Type, market is studied across Cystic Fibrosis, Lactose Intolerance, and Sprue.
  • Based on End-user, market is studied across Academic & Research Institutes, Hospitals, Nutrition Clinics, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of lactose intolerance consumers
      • 5.1.1.2. Favorable government initiatives and awareness campaigns for malabsorption syndrome
      • 5.1.1.3. Growing incidences of cause disorders such as celiac disease and other digestive diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of proper healthcare infrastructure
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing regulatory approvals and clinical trials of treating malabsorption syndrome
      • 5.1.3.2. Investments and development of novel medicines
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent safety rules and product recalls
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Malabsorption Syndrome Market, by Treatment

  • 6.1. Introduction
  • 6.2. Anti-Inflammatory Drugs
  • 6.3. Antibiotics
  • 6.4. Antidiarrheal Agents
  • 6.5. Gluten-Free Diet
  • 6.6. Nutritional Supplements
  • 6.7. Protease & Lipase Supplements

7. Malabsorption Syndrome Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Cystic Fibrosis
  • 7.3. Lactose Intolerance
  • 7.4. Sprue

8. Malabsorption Syndrome Market, by End-user

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Hospitals
  • 8.4. Nutrition Clinics
  • 8.5. Pharmaceutical Companies

9. Americas Malabsorption Syndrome Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Malabsorption Syndrome Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Malabsorption Syndrome Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Ache Laboratorios Farmaceuticos S.A.
  • 3. AstraZeneca PLC
  • 4. Bausch Health Companies Inc.
  • 5. Baxter International Inc.
  • 6. Bayer AG
  • 7. Gilead Sciences, Inc.
  • 8. GlaxoSmithKline PLC
  • 9. Koninklijke Philips N.V.
  • 10. Merck & Co., Inc.
  • 11. Novartis AG
  • 12. Perrigo Company PLC
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Tillotts Pharma AG

LIST OF FIGURES

  • FIGURE 1. MALABSORPTION SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. MALABSORPTION SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MALABSORPTION SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MALABSORPTION SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ANTIDIARRHEAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY GLUTEN-FREE DIET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PROTEASE & LIPASE SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY LACTOSE INTOLERANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY SPRUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY NUTRITION CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MALABSORPTION SYNDROME MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES MALABSORPTION SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM MALABSORPTION SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. MALABSORPTION SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. MALABSORPTION SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023